Investor Presentation Full Year 2021

123 Investor presentation Full year 2021 Solid operating profit growth driven by Diabetes care Operating profit DKK billion 70 Percent of sales 60% 60 50 40 20 IN WO 50% 40% 30% 30 1% -4% 11% 3% 8% 20% 78% 10 5% 3% 6% 7% 13% 10% 0 0% 2017 2019 2020 2021 2018 Operating profit Operating profit as % of sales Reported operating profit growth Operating profit growth at CER CER: Constant exchange rates Operating profit split per franchise 22% 84% 2017 2021 Diabetes and Obesity care Biopharm 16% Novo NordiskⓇ

View entire presentation